Company Description
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.
The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia.
The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited.
Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 2013 |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 800 |
| CEO | Najat Khan |
Contact Details
Address: 41 South Rio Grande Street Salt Lake City, Utah 84101 United States | |
| Phone | 385 269 0203 |
| Website | recursion.com |
Stock Details
| Ticker Symbol | RXRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001601830 |
| CUSIP Number | 75629V104 |
| ISIN Number | US75629V1044 |
| Employer ID | 46-4099738 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Najat Khan Ph.D. | Chief Executive Officer, President and Director |
| Dr. Christopher C. Gibson Ph.D. | Co-Founder, Chairman and Interim Executive Advisor |
| Ben R. Taylor | Chief Financial Officer and President of Recursion UK |
| Dr. David J. Mauro M.D., Ph.D. | Chief Medical Officer |
| Kristen Rushton M.B.A. | Chief Operating Officer |
| Benjamin Mabey M.S. | Chief Technology Officer |
| Dr. David Hallett Ph.D. | Chief Scientific Officer |
| Nathan Hatfield J.D., M.B.A. | Chief Legal Officer and Corporate Secretary |
| Ryan Kelly | Chief Communications Officer |
| Erica Fox | Chief People and Impact Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | 144 | Filing |
| Feb 25, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2026 | 424B5 | Filing |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 19, 2026 | 144 | Filing |
| Feb 18, 2026 | 144 | Filing |
| Feb 5, 2026 | SCHEDULE 13G/A | Filing |
| Feb 4, 2026 | 144 | Filing |
| Feb 3, 2026 | SCHEDULE 13G/A | Filing |